Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Background: Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is associated with potentially life-threatening toxicities, most commonly cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS). These frequent adverse events are managed with the I...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakomy, Tim, Akhoundova, Dilara, Nilius, Henning, Kronig, Marie-Noëlle, Novak, Urban, Daskalakis, Michael, Bacher, Ulrike, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953517/
https://www.ncbi.nlm.nih.gov/pubmed/36830750
http://dx.doi.org/10.3390/biom13020382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953517/
https://www.ncbi.nlm.nih.gov/pubmed/36830750
http://dx.doi.org/10.3390/biom13020382

Ejemplares similares